Human papilloma virus (HPV) positive and HPV negative head and neck squamous cell cancer (HNSCC) are biologically distinct with a prognostic advantage for HPV positive patients compared to HPV negative cases. DNA promoter methylation is central to human diseases such as cancer, including HNSCC, with reported genome-wide hypomethylaton and promoter hypermethylation in HPV positive HNSCC tumors. The goal of this study was to identify differentially methylated genes in HPV positive versus HPV negative primary HNSCC genomes with clues to signaling networks.
Study Design
Laboratory-based study.
Setting
Primary care academic health care system.
Subjects and Methods
DNA from 4 HPV positive and 4 HPV negative freshly frozen primary HNSCC were subject to comprehensive genome-wide methylation profiling. Differentially methylated gene lists were examined using the Signal Transduction Pathways (canonical) filter in the Genomatix Pathway System (GePS).
Results
Twofold methylation differences were observed between HPV positive and HPV negative cases for 1168 genes. Pathway analysis applied to investigate the biological role of the 1168 differentially methylated genes revealed 8 signal transduction pathways forming a network of 66 genes, of which 62% are hypermethylated.
Conclusion
Our study reveals a predominant hypermethylation profile for genes in signal transduction pathways of HPV positive HNSCC tumor genomes. Because signaling events in the cell play a critical role in the execution of key biological functions, insights into how complex cellular signaling cascades and networks may be programmed in HNSCC are likely to be critical in the development of new biological agents designed to hit multiple targets.
HornerMJRiesLAGKrapchoM (Eds.). SEER cancer statistics review, 1975-2006, section 16: melanoma of the skin. http://seer.cancer.gov/csr/1975_2006/. 2009. Accessed March 29, 2010.
2.
HashibeMBrennanPBenhamouS. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst. 2007;99:777-789.
3.
HashibeMBrennanPChuangSC. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18:541-550.
4.
GillisonMLLowyDR. A causal role for human papillomavirus in head and neck cancer. Lancet. 2004;363:1488-1489.
5.
AngKKHarrisJWheelerR. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35.
6.
DayyaniFEtzelCJLiuM. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010;2:15.
7.
KreimerARCliffordGMBoyleP. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14:467-475.
8.
GillisonML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol. 2004;31:744-754.
9.
MungerKBaldwinAEdwardsKM. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78:11451-11460.
10.
NguyenMSongSLiemA. A mutant of human papillomavirus type 16 E6 deficient in binding alpha-helix partners displays reduced oncogenic potential in vivo. J Virol. 2002;76:13039-13048.
11.
FakhryCWestraWHLiS. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261-269.
12.
SartorMADolinoyDCJonesTR. Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics. 2011;6:777-787.
13.
RichardsKLZhangBBaggerlyKA. Genome-wide hypomethylation in head and neck cancer is more pronounced in HPV-negative tumors and is associated with genomic instability. PLoS One. 2009;4:e4941.
14.
LumPYChenYZhuJ. Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. J Neurochem. 2006;97(suppl 1):50-62.
ChenYZhuJLumPY. Variations in DNA elucidate molecular networks that cause disease. Nature. 2008;452:429-435.
17.
GargalovicPSImuraMZhangB. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc Natl Acad Sci U S A. 2006;103:12741-12746.
18.
HorvathSZhangBCarlsonM. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A. 2006;103:17402-174067.
19.
StephenJKChenKMShahV. Human papillomavirus outcomes in an access-to-care laryngeal cancer cohort. Otolaryngol Head Neck Surg. 2012;146:730-738.
20.
StephenJS DGChenKMChitaleDHavardSWorshamMJ. Significance of p16 in site-specific HPV positive and HPV negative head and neck squamous cell carcinoma. Cancer Clin Oncol. 2013;2:51-61.
21.
WorshamMJStephenJKChenKM. Improved survival with HPV among African Americans with oropharyngeal cancer. Clin Cancer Res. In press.
22.
FrischMKlockeBHaltmeierM. LitInspector: literature and signal transduction pathway mining in PubMed abstracts. Nucleic Acids Res. 2009;37:W135-W140.
23.
GillisonMLKochWMCaponeRB. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709-720.
24.
HafkampHCSpeelEJHaesevoetsA. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer. 2003;107:394-400.
25.
LicitraLPerroneFBossiP. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2006;24:5630-5636.
26.
SlebosRJYiYElyK. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12:701-709.
27.
SmithEMWangDKimY. P16INK4a expression, human papillomavirus, and survival in head and neck cancer. Oral Oncol. 2008;44:133-142.
28.
RaginCCTaioliEWeissfeldJL. 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. Br J Cancer. 2006;95:1432-1438.
29.
BraakhuisBJSnijdersPJKeuneWJ. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst. 2004;96:998-1006.
30.
SmeetsSJBraakhuisBJAbbasS. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene. 2006;25:2558-2564.
31.
DahlgrenLMellinHWangsaD. Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors. Int J Cancer. 2003;107:244-249.
32.
MartinezIWangJHobsonKF. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer. 2007;43:415-432.
33.
StranskyNEgloffAMTwardAD. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333:1157-1160.
34.
AgrawalNFrederickMJPickeringCR. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333:1154-1157.
35.
GubanovaEBrownBIvanovSV. Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival. Clin Cancer Res. 2012;18:1257-1267.
36.
VoronkovAKraussS. Wnt/beta-catenin signaling and small molecule inhibitors. Curr Pharm Des. 2013;19:634-664.
37.
CleversH. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127:469-480.
38.
CleversHNusseR. Wnt/beta-catenin signaling and disease. Cell. 2012;149:1192-1205.
UrenAFallenSYuanH. Activation of the canonical Wnt pathway during genital keratinocyte transformation: a model for cervical cancer progression. Cancer Res. 2005;65:6199-6206.
41.
Rodriguez-SastreMAGonzalez-MayaLDelgadoR. Abnormal distribution of E-cadherin and beta-catenin in different histologic types of cancer of the uterine cervix. Gynecol Oncol. 2005;97:330-336.
42.
ShinoharaAYokoyamaYWanX. Cytoplasmic/nuclear expression without mutation of exon 3 of the beta-catenin gene is frequent in the development of the neoplasm of the uterine cervix. Gynecol Oncol. 2001;82:450-455.
43.
BulutGFallenSBeauchampEM. Beta-catenin accelerates human papilloma virus type-16 mediated cervical carcinogenesis in transgenic mice. PLoS One. 2011;6:e27243.
44.
RampiasTBoutatiEPectasidesE. Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res. 2010;8:433-443.
45.
AguileraOMunozAEstellerM. Epigenetic alterations of the Wnt/beta-catenin pathway in human disease. Endocr Metab Immune Disord Drug Targets. 2007;7:13-21.
46.
PannoneGBufoPSantoroA. WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors. Oncol Rep. 2010;24:1035-1041.
47.
TakeichiM. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol. 1993;5:806-811.
48.
OnderTTGuptaPBManiSA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008;68:3645-3654.
49.
GeorgopoulosNTKirkwoodLAWalkerDC. Differential regulation of growth-promoting signalling pathways by E-cadherin. PLoS One. 2010;5:e13621.
50.
WangDSLHuangDZhangHShinDChenZ. Downregulation of E-cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR. Molecular Cancer. 2011;10:116.
51.
ModjtahediHDeanC. The receptor for EGF and its ligands—expression, prognostic value and target for therapy in cancer (review). Int J Oncol. 1994;4:277-296.
52.
GrandisJRTweardyDJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53:3579-3584.
53.
OngkekoWMAltunaXWeismanRA. Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol. 2005;124:71-76.
54.
SheuJJHuaCHWanL. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res. 2009;69:2568-2576.
55.
KimSGrandisJRRinaldoA. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck. 2008;30:667-674.
56.
Rubin GrandisJMelhemMFGoodingWE. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90:824-832.
57.
TemamSKawaguchiHEl-NaggarAK. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol. 2007;25:2164-2170.
58.
ChungCHElyKMcGavranL. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol. 2006;24:4170-4176.
59.
AngKKBerkeyBATuX. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350-7356.
60.
GrandisJRTweardyDJ. TGF-alpha and EGFR in head and neck cancer. J Cell Biochem Suppl. 1993;17F:188-191.
61.
GrandisJRChakrabortyAZengQ. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem. 1998;69:55-62.
62.
EriksenJGSteinicheTSogaardH. Expression of integrins and E-cadherin in squamous cell carcinomas of the head and neck. Apmis. 2004;112:560-568.
63.
DesgrosellierJSChereshDA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9-22.
64.
CordesNSeidlerJDurzokR. beta1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene. 2006;25:1378-1390.
65.
EkeIDeuseYHehlgansS. beta(1)Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J Clin Invest. 2012;122:1529-1540.
66.
SurapureddiSYuSBuH. Identification of a transcriptionally active peroxisome proliferator-activated receptor alpha-interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator. Proc Natl Acad Sci U S A. 2002;99:11836-11841.
67.
LibbyP. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-372.
JaeckelECRajaSTanJ. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2001;127:1253-1259.
70.
RossSAMcCafferyPJDragerUC. Retinoids in embryonal development. Physiol Rev. 2000;80:1021-1054.
71.
LotanRLotanDSacksPG. Inhibition of tumor cell growth by retinoids. Methods Enzymol. 1990;190:100-110.
72.
RossSAJonesCSDe LucaLM. Retinoic acid and methotrexate specifically increase PHA-E-lectin binding to a 67-kDa glycoprotein in LA-N-1 human neuroblastoma cells. Int J Cancer. 1995;62:303-308.
73.
ShenPF. Molecular mechanisms of chemoprevention and therapy of cancer by retinoids. Front Biosci. 2004;9:2663-2670.
74.
SunSYLotanR. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol. 2002;41:41-55.
75.
Pitha-RoweIPettyWJFengQ. Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res. 2004;64:8109-8115.
76.
ChanLSWellsRA. Cross-talk between PPARs and the partners of RXR: a molecular perspective. PPAR Res. 2009;2009:925309.
77.
LiMXiongZG. Ion channels as targets for cancer therapy. Int J Physiol Pathophysiol Pharmacol. 2011;3:156-166.
78.
HerbstRSHongWK. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin Oncol. 2002;29:18-30.
79.
KimESKiesMHerbstRS. Novel therapeutics for head and neck cancer. Curr Opin Oncol. 2002;14:334-342.
80.
HarrisGGhazallahRANasceneD. PPAR activation and decreased proliferation in oral carcinoma cells with 4-HPR. Otolaryngol Head Neck Surg. 2005;133:695-701.
81.
OldenKIsaacLRobertsL. Neighborhood-specific epigenome analysis: the pathway forward to understanding gene-environment interactions. N C Med J. 2011;72:125-127.
82.
GarberK. Breaking the silence: the rise of epigenetic therapy. J Natl Cancer Inst. 2002;94:874-875.
83.
KopelovichLCrowellJAFayJR. The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst. 2003;95:1747-1757.
84.
LuDHooryTMonieA. Treatment with demethylating agent, 5-aza-2’-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine. 2009;27:4363-4369.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
